Guideline-concordant antidepressant use among patients with major depressive disorder - 11/08/11
, Richard A. Hansen, Ph.D. b, Bradley N. Gaynes, M.D., M.P.H. c, Joel F. Farley, Ph.D. b, Joseph P. Morrissey, Ph.D. c, d, e, Matthew L. Maciejewski, Ph.D. f, gAbstract |
Objectives |
To examine whether prescriber specialty and guideline-concordant follow-up visits were associated with antidepressant treatment completion among patients with major depressive disorder (MDD).
Methods |
This study analyzed medical and prescription claims from a large national health plan. Patients were grouped based on initial prescriber specialty. Receipt of guideline-concordant follow-ups was defined as having ≥3 visits during the treatment phase. Completion of acute phase (first 90 days) and continuation phase (Days 91–270) was defined by adherence ≥80% without significant gaps in treatment. Logistic regressions were used to examine factors associated with treatment completion.
Results |
Forty-seven percent of the 4102 newly diagnosed patients completed the acute phase, 45% of whom also completed the continuation phase. Among those initially prescribed by primary care providers (PCPs), patients with guideline-concordant follow-ups were more likely (13.1 percentage points, P<.0001) to complete acute phase than patients without guideline-concordant follow-ups. Receipt of guideline-concordant follow-ups increased the probability of acute phase completion by an additional 6.8 percentage points if initially treated by psychiatrists. Patients prescribed by psychiatrists were less likely to complete acute phase treatment (−4.6 percentage points, P=.04) if they did not have guideline-concordant follow-ups.
Conclusion |
A large gap remains between guideline recommendations and actual antidepressant treatment. Frequent follow-up corresponds with better antidepressant adherence.
Le texte complet de cet article est disponible en PDF.Keywords : Depression, Antidepressants, Provider specialty, Clinical guideline, Follow-up visits
Plan
| ☆ | Conflict of interest statement: Dr. Hansen is supported by grant KL2RR025746 from the National Center for Research Resources. A portion of this work was funded by the American Association of Colleges of Pharmacy New Investigator Program (NIP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources, the National Institutes of Health or the American Association of Colleges of Pharmacy. Dr. Chen is employed by Abt Bio-Pharma Solutions. Dr. Hansen has received consulting fees from Takeda Pharmaceuticals. Dr. Farley has received grant funding from the Pfizer Foundation and consulting fees from Takeda Pharmaceuticals. Dr. Gaynes has received grants and research support from M-3 Information, Bristol-Myers Squibb Company and Novartis, and he has served as an advisor for Bristol-Myers Squibb Company. The other authors report no competing interests. |
Vol 32 - N° 4
P. 360-367 - juillet 2010 Retour au numéro
Article précédent
- The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review
- Kurt Kroenke, Robert L. Spitzer, Janet B.W. Williams, Bernd Löwe
- Quality of care for anxiety and depression in different ethnic groups by family practitioners in urban areas in the Netherlands
- Thijs Fassaert, Mark Nielen, Robert Verheij, Arnoud Verhoeff, Jack Dekker, Aartjan Beekman, Matty de Wit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?